Keywords: circassia, acquires, rights, dopexamine, ipsen, uk-based, specialty

Circassia acquires rights to dopexamine from Ipsen

Article | 13 October 2008

Print This

Circassia, a UK-based specialty biopharmaceutical company focused on the fields of allergy and critical care, has acquired the US, Canadian ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in